scholarly journals Phenotypes, genotypes and disease susceptibility associated with gene copy number variations: complement C4 CNVs in European American healthy subjects and those with systemic lupus erythematosus

2008 ◽  
Vol 123 (1-4) ◽  
pp. 131-141 ◽  
Author(s):  
Y.L. Wu ◽  
Y. Yang ◽  
E.K. Chung ◽  
B. Zhou ◽  
K.J. Kitzmiller ◽  
...  
2019 ◽  
Vol 59 (1) ◽  
Author(s):  
Kaline Medeiros Costa Pereira ◽  
Sandro Perazzio ◽  
Atila Granado A. Faria ◽  
Eloisa Sa Moreira ◽  
Viviane C. Santos ◽  
...  

Rheumatology ◽  
2011 ◽  
Vol 50 (7) ◽  
pp. 1201-1205 ◽  
Author(s):  
Bo Yu ◽  
Yong Shao ◽  
Xupeng Yue ◽  
Jie Zhang ◽  
Ming Guan ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Danlei Zhou ◽  
Michael Rudnicki ◽  
Gilbert T. Chua ◽  
Simon K. Lawrance ◽  
Bi Zhou ◽  
...  

Human complement C4 is one of the most diverse but heritable effectors for humoral immunity. To help understand the roles of C4 in the defense and pathogenesis of autoimmune and inflammatory diseases, we determined the bases of polymorphisms including the frequent genetic deficiency of C4A and/or C4B isotypes. We demonstrated the diversities of C4A and C4B proteins and their gene copy number variations (CNVs) in healthy subjects and patients with autoimmune disease, such as type 1 diabetes, systemic lupus erythematosus (SLE) and encephalitis. We identified subjects with (a) the fastest migrating C4B allotype, B7, or (b) a deficiency of C4B protein caused by genetic mutation in addition to gene copy-number variation. Those variants and mutants were characterized, sequenced and specific techniques for detection developed. Novel findings were made in four case series. First, the amino acid sequence determinant for C4B7 was likely the R729Q variation at the anaphylatoxin-like region. Second, in healthy White subject MS630, a C-nucleotide deletion at codon-755 led to frameshift mutations in his single C4B gene, which was a private mutation. Third, in European family E94 with multiplex lupus-related mortality and low serum C4 levels, the culprit was a recurrent haplotype with HLA-A30, B18 and DR7 that segregated with two defective C4B genes and identical mutations at the donor splice site of intron-28. Fourth, in East-Asian subject E133P with anti-NMDA receptor encephalitis, the C4B gene had a mutation that changed tryptophan-660 to a stop-codon (W660x), which was present in a haplotype with HLA-DRB1*04:06 and B*15:27. The W660x mutation is recurrent among East-Asians with a frequency of 1.5% but not detectable among patients with SLE. A meticulous annotation of C4 sequences revealed clusters of variations proximal to sites for protein processing, activation and inactivation, and binding of interacting molecules.


2019 ◽  
Vol 23 (8) ◽  
pp. 5340-5348
Author(s):  
Man Zhang ◽  
Yuanyuan Gu ◽  
Shunwei Huang ◽  
Qiuyue Lou ◽  
Qiaomei Xie ◽  
...  

2019 ◽  
Vol 6 (1) ◽  
pp. e000333 ◽  
Author(s):  
Evan Mulvihill ◽  
Stacy Ardoin ◽  
Susan D Thompson ◽  
Bi Zhou ◽  
Gakit Richard Yu ◽  
...  

ObjectiveSystemic lupus erythematosus (SLE) features high frequency of cardiovascular disease (CVD) and fluctuating complement levels. The clinical trial Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) aimed to evaluate whether atorvastatin treatment reduced the progression of atherosclerosis in 221 patients with childhood-onset SLE (cSLE), using carotid intima media thickness (CIMT) as surrogates. We leveraged APPLE biorepository and trial data to investigate the relationship between complement and CVD in cSLE.MethodsGene copy numbers (GCNs) for total C4, C4A and C4B were measured by TaqMan-based real-time PCR and Southern blotting, and analysed with laboratory and clinical parameters through Student’s t-test and χ2 analyses. Effects of total C4, C4A and C4B GCNs on the response to placebo or atorvastatin treatment and progression of CIMT were examined by regression analyses.ResultsAt baseline, C4 protein levels strongly correlated with GCNs of total C4 (p=1.8×10−6). Each copy of C4 gene increased mean serum C4 by 3.28 mg/dL. Compared with those without hypertension (N=142), individuals with hypertension demonstrated significantly elevated serum levels for C4 and C3 at baseline and serially (C4: P=5.0×10−25; C3: P=5.84×10−20). Individuals with ≥2 C4B genes had 2.5 times the odds of having hypertension (p=0.016) and higher diastolic blood pressure (p=0.015) compared with those with C4B deficiency. At the study end, subjects with ≥2 C4B and atorvastatin treatment had significantly slower increase in CIMT compared with those treated with placebo (p=0.018).ConclusionscSLE with hypertension had elevated serum levels of C4 and C3 and higher GCN of C4B; cSLE with ≥2 C4B genes would benefit from statins therapy to prevent atherosclerosis.


Sign in / Sign up

Export Citation Format

Share Document